As demand for biosimilar development swells around the world, CRO inVentiv Health has teamed up with Australia's Proteomics International to expand its characterization services, an effort to boost its capabilities in early work on biologic knockoffs.
Under the deal, Proteomics International will lend its expertise in structural characterization and quality control testing of proposed and reference drugs, providing a bridge to inVentiv's existing services in bioanalytics, clinical development and commercialization, the two said. That allows clients to easily transition from characterization to clinical trials, inVentiv said, giving them a competitive advantage in the race to cash in on off-patent biologics.
"The strengths of Proteomic International to demonstrate biosimilarity combined with inVentiv biologic clinical, commercial and consulting expertise is a winning solution for clients," inVentiv Vice President George Scott said in a statement. "Together we offer the full breadth and scope of an integrated road map of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct and registration to commercialization."
The partnership is part of a sweeping biosimilars effort on inVentiv's part, following a revenue-sharing deal with Oncobiologics in which the duo will collaborate on knockoffs of on Humira, Rituxan, Avastin, Herceptin and Erbitux, drugs that have generated a combined $40 billion around the globe.
- read the statement (PDF)